I am the lead scientist of the diabetes ‘omics’ research for the Hoorn study, the new Hoorn study and the Hoorn Diabetes Care System cohort (DCS). My group has performed extensive research in the field of genetics of type 2 diabetes with special focus on deep phenotyping studies, mitochondrial function and progression of type 2 diabetes. Furthermore, I have a strong interest in functional studies to further elucidate functional mechanisms behind the observed associations.
Using data from the DCS cohort we for instance showed that several gene variants impact on response to metformin and or DPP-4 inhibitor treatment in type 2 diabetes patients. In addition my team has identified several metabolites in blood that predict incident type 2 diabetes or diabetes progression defined as initiation of insulin secretion. During the last few years we expanded our research into other omics, exploring the potential of genomics, metabolomics, proteomics and transcriptomics in stratification of patients according their risk for rapid progression of diabetes and development of diabetic complications. www.hoornstudies.com
I was trained in biotechnology (1991), and started my academic career at Leiden University working on a project regarding plant genetics. In 1993 I joined the group of Prof JA Maassen at Leiden University Medical Center (LUMC) as a research technician working on genetic aspects of diabetes and especially mitochondrial diabetes. In 2002 I obtained my PhD on a thesis titled “Genetic analysis of type 2 diabetes, insulin resistance and insulin secretion” with Profs JA Maassen (LUMC) en RJ Heine (VUmc) as promotors. I am also affiliated with the Biomedical Data Sciences department of the LUMC and the Department of Epidemiology and Biostatistics at the Amsterdam UMC, location VUmc.
HbA1c is associated with altered expression in blood of cell cycle- and immune response-related genes.
Slieker RC, van der Heijden A, van Leeuwen N, et al.
Diabetologia 61: 138-146
Metabolite ratios as potential biomarkers for type 2 diabetes: a DIRECT study.
Molnos S, Wahl S, Haid M, et al.
Diabetologia 61: 117-129
The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway.
't Hart LM, Fritsche A, Nijpels G, et al.
Diabetes 62: 3275-3281